These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 34758676

  • 1. The role of sulfonylureas in the treatment of type 2 diabetes.
    Tomlinson B, Patil NG, Fok M, Chan P, Lam CWK.
    Expert Opin Pharmacother; 2022 Feb; 23(3):387-403. PubMed ID: 34758676
    [Abstract] [Full Text] [Related]

  • 2. Evaluating gliclazide for the treatment of type 2 diabetes mellitus.
    Tomlinson B, Li YH, Chan P.
    Expert Opin Pharmacother; 2022 Dec; 23(17):1869-1877. PubMed ID: 36300277
    [Abstract] [Full Text] [Related]

  • 3. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
    Colagiuri S, Matthews D, Leiter LA, Chan SP, Sesti G, Marre M.
    Diabetes Res Clin Pract; 2018 Sep; 143():1-14. PubMed ID: 29802958
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin.
    Wang MT, Pan HY, Huang YL, Wu LW, Wang PC, Hsu YJ, Lin TC, Lin C, Lai JH, Lee CH.
    JAMA Netw Open; 2022 Dec 01; 5(12):e2245854. PubMed ID: 36484988
    [Abstract] [Full Text] [Related]

  • 5. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
    Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S.
    BMJ; 2018 Jul 18; 362():k2693. PubMed ID: 30021781
    [Abstract] [Full Text] [Related]

  • 6. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes].
    Rustenbeck I.
    Med Monatsschr Pharm; 2016 Feb 18; 39(2):65-72; quiz 73-4. PubMed ID: 26983335
    [Abstract] [Full Text] [Related]

  • 7. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
    Yu O, Azoulay L, Yin H, Filion KB, Suissa S.
    Am J Med; 2018 Mar 18; 131(3):317.e11-317.e22. PubMed ID: 29032229
    [Abstract] [Full Text] [Related]

  • 8. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
    Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT, MASTERMIND Consortium.
    Diabetes Care; 2018 Sep 18; 41(9):1844-1853. PubMed ID: 30072404
    [Abstract] [Full Text] [Related]

  • 9. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, Wang SJ, Yang CY, Lin CC, Chen TJ, Tarng DC, Li SY, Chen YT.
    Ann Intern Med; 2015 Nov 03; 163(9):663-72. PubMed ID: 26457538
    [Abstract] [Full Text] [Related]

  • 10. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G, Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group, Italian Diabetes Society.
    Lancet Diabetes Endocrinol; 2017 Nov 03; 5(11):887-897. PubMed ID: 28917544
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.
    Hougen I, Whitlock RH, Komenda P, Rigatto C, Clemens KK, Tangri N.
    BMJ Open Diabetes Res Care; 2021 Dec 03; 9(2):. PubMed ID: 34969692
    [Abstract] [Full Text] [Related]

  • 14. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Nutter B, Jain A, Atreja A, Zimmerman RS.
    Diabet Med; 2012 Aug 03; 29(8):1029-35. PubMed ID: 22248043
    [Abstract] [Full Text] [Related]

  • 15. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK, Singh R.
    Expert Rev Clin Pharmacol; 2016 Jun 03; 9(6):839-51. PubMed ID: 26924475
    [Abstract] [Full Text] [Related]

  • 16. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L.
    J Am Heart Assoc; 2020 Jan 07; 9(1):e012940. PubMed ID: 31902326
    [Abstract] [Full Text] [Related]

  • 17. The role of glimepiride in the effective management of Type 2 diabetes.
    Davis SN.
    J Diabetes Complications; 2004 Jan 07; 18(6):367-76. PubMed ID: 15531188
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
    Hsu PF, Sung SH, Cheng HM, Shin SJ, Lin KD, Chong K, Yen FS, Yu BH, Huang CT, Hsu CC.
    J Clin Endocrinol Metab; 2018 Oct 01; 103(10):3611-3619. PubMed ID: 30113697
    [Abstract] [Full Text] [Related]

  • 19. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.
    Harrower AD.
    J Diabetes Complications; 1994 Oct 01; 8(4):201-3. PubMed ID: 7833494
    [Abstract] [Full Text] [Related]

  • 20. Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis.
    Romley JA, Gong C, Jena AB, Goldman DP, Williams B, Peters A.
    BMJ; 2015 Dec 07; 351():h6223. PubMed ID: 26643108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.